九州通：关于盐酸异丙嗪注射液获得药品注册证书的公告

Core Viewpoint - The announcement indicates that a subsidiary of the company has received regulatory approval for a new drug, which may enhance its product portfolio and market position in the pharmaceutical industry [2] Group 1 - On December 26, the company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received a drug registration certificate for Isopropamide Iodide Injection from the National Medical Products Administration [2] - The approval is significant as it allows the company to market and distribute this medication, potentially increasing its revenue streams [2] - The drug registration certificate was issued on December 25, 2025, marking a key milestone in the company's product development timeline [2]